The article reflects on the clinical challenges of managing type 2 diabetes and the potential of glucagon-like peptide-1 (GLP-1) based therapies. It is said that deficiencies in the traditional pharmacological therapies for type 2 diabetes have led to the development of a number of novel treatments. GLP-1 receptor agonists have garnered considerable interest in terms of their efficacy.